Navigation Links
Nasdaq Informs Synutra that the Company's Filing Delinquency has been Cured
Date:10/11/2007

QINGDAO, China and ROCKVILLE, Md., Oct. 11 /Xinhua-PRNewswire/ -- On October 10, 2007, Synutra International, Inc. (Nasdaq: SYUT; "Synutra"), one of China's leading manufacturers of dairy-based nutritional products for infants, children and adults, received a letter from the Nasdaq Stock Market stating that the Company's common stock is no longer subject to delisting following the filing with the SEC on October 5, 2007 of the Company's quarterly report on Form 10-Q for the period ended June 30, 2007. Upon review of the filing, the Nasdaq staff determined that Synutra meets all listing criteria and is in compliance with Nasdaq Marketplace Rule 4310(c)(14), which states that timely filing of annual and periodic reports with the SEC is required for continued listing. Accordingly, the Company's scheduled hearing before Nasdaq's Listing Qualifications Panel has been considered moot.

About Synutra International, Inc.

Synutra operates eight subsidiaries developing, producing, distributing and selling dairy-based nutritional products across the People's Republic of China. It offers its products for infants, children, adults and pregnant women and nursing mothers under the brand series of "Super," "U-Smart" and "U- Strong." The Group's extensive sales network covers 24 provinces, 264 cities and more than 1320 counties throughout China. For more information, please contact Weiguo Zhang of Synutra, Inc. (+1-301-840-3888, wzhang@synutra.com), Brian Rafferty of Taylor Rafferty (+1-212-889-4350, synutra@taylor-rafferty.com) or visit: http://www.synutra.com.

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

For more information, please contact:

Mr. Weiguo Zhang, Synutra, Inc.

Phone: +1-301-840-3888

Email: wzhang@synutra.com

Mr. Brian Rafferty

Taylor Rafferty

Phone: +1-212-889-4350

Email: synutra@taylor-rafferty.com


'/>"/>
SOURCE Synutra International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Patna To Receive Better Health Care Facility Informs Health Minister
2. Nutrient Profiling System Launched By Food Officials in UK
3. Proteomic Profiling Can Detect Preterm Birth Risk
4. Brains Filing System Uncovered
5. Profiling of Cancer Genes May Lead to Earlier Detection Human Cancers
6. Sweaty palms syndrome can be cured by surgery
7. Muscular Dystrophy May Be Cured By Gene Therapy
8. Back injury cured by engineers
9. Multiple organ disease cured by genes
10. Hay fever may be cured by self-hypnosis
11. Women cured of anorexia nervosa have redistributed body fat after weight gain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: